Amsterdam

• First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leuk … Ended
  2023-508357-58-00 7 2022-07-04 Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myel
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 10 2022-06-30 Pulmonary Arterial Hypertension (PAH)
• A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon … Ended
  2023-506981-30-00 4 2022-05-25 Chronic kidney disease in type 2 diabetes mellitus
• A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients. Ended
  2023-509139-16-00 5 2022-05-13 Therapeutic confirmatory (phase III)
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• Study of Personalized Neoantigen Specific TCR T cells in the Treatment of Advanced Solid Cancers Ended
  2024-518201-18-00 1 2022-04-28 Advanced Solid Cancers
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• A study to evaluate Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality Ended
  2023-509140-10-00 5 2022-04-05 Pulmonary Arterial Hypertension (PAH)
• A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patient … Ended
  2024-514130-20-00 5 2022-04-04 complement 3 glomerulopathy (C3G)/immune complex membranoproliferativ
• Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom … Ended
  2024-511361-11-00 10 2022-03-25 Advanced dedifferentiated liposarcoma
• A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended
  2024-513304-33-00 5 2022-03-17 Type 1 diabetes mellitus
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia. Ended
  2024-510696-38-00 5 2022-03-08 Severe Hypertriglyceridemia.
• Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1 Ended
  2024-514907-32-00 3 2022-01-21 non-metastatic soft tissue sarcoma
• Tolerability of concurrent EBRT + Lu-PSMA for node-positive prostate cancer (PROQURE-1) Ended
  2024-514168-15-00 3 2021-12-17 N+M0 prostate cancer
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Oc … Ended
  2022-502542-28-00 4 2021-12-06 Sickle Cell Disease
• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects with Geographic Atrophy Secondary to … Ended
  2024-512945-18-00 5 2021-11-30 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• LAVA1207-001/LAVA1207-002 A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immun … Ended
  2024-515821-27-00 9 2021-11-30 Prostate Cancer
• A Phase 2 Study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia os … Ended
  2024-511469-13-00 4 2021-10-19 Fibrodysplasia Ossificans Progressiva
• A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancer Ended
  2022-502774-17-00 7 2021-10-04 Advanced or metastatic gastric and gastro-esophageal junction (GEJ) ad
• A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended
  2023-503813-31-01 5 2021-09-17 Second- or Third-Line Recurrent or Metastatic Cervical Cancer
• 7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended
  2023-505284-36-00 4 2021-09-13 Advanced solid tumors
• A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) Ended
  2023-508340-22-00 4 2021-08-11 metastatic or unresectable, recurrent HNSCC
• A Phase 2 study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma … Ended
  2023-508342-17-00 4 2021-08-11 metastatic or unresectable, recurrent HNSCC
• A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan … Ended
  2024-513569-38-00 10 2021-07-09 Crohn's Disease

Showing 1,009–1,032 of 1,112 trials